Literature DB >> 11380478

Non-transferrin-bound iron during allogeneic stem cell transplantation.

L Sahlstedt1, F Ebeling, L von Bonsdorff, J Parkkinen, T Ruutu.   

Abstract

Hydroxyl radical formation catalysed by non-transferrin-bound iron (NTBI) might contribute to transplantation-related complications. The occurrence of NTBI in 10 adult allogeneic stem cell transplantation (SCT) patients was followed for 20 d. The transferrin saturation reached 99% on d -4 and remained > 80% thereafter. NTBI, measured as bleomycin-detectable iron, was detected for 6-18 d in all patients with a peak on d -4. High transferrin saturation levels were associated with the appearance of NTBI with a threshold at 80% saturation. Prevention of the potential deleterious effects of NTBI might reduce transplantation-related morbidity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380478     DOI: 10.1046/j.1365-2141.2001.02820.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  27 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

3.  Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy.

Authors:  M Tanaka; H Kanamori; K Matsumoto; T Tachibana; A Numata; K Ohashi; T Kobayashi; C Nakaseko; Y Kanda; E Yamazaki; S Fujisawa; J Ooi; T Sakura; N Aotsuka; M Onoda; S Machida; J Kato; K Usuki; R Watanabe; J Taguchi; S Yano; T Saito; S Takahashi; H Sakamaki; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

Review 4.  The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2017-11-13       Impact factor: 2.490

5.  Does iron overload really matter in stem cell transplantation?

Authors:  Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

Review 6.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

7.  Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.

Authors:  P Armand; M-M Sainvil; H T Kim; J Rhodes; C Cutler; V T Ho; J Koreth; E P Alyea; E J Neufeld; R Y Kwong; R J Soiffer; J H Antin
Journal:  Bone Marrow Transplant       Date:  2012-05-21       Impact factor: 5.483

Review 8.  How we manage iron overload in sickle cell patients.

Authors:  Thomas D Coates; John C Wood
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 9.  The potential adverse effects of haemolysis.

Authors:  Francesca Rapido
Journal:  Blood Transfus       Date:  2017-05       Impact factor: 3.443

10.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.